Eversept Partners dropped a cool $28 million on Avantor stock. February 17th, to be exact. 2,252,202 shares. A gamble, some might say. Others, a calculated risk. I’ve seen enough paper shuffling to know it’s rarely either.
The Setup
The filing, dated February 17th, showed Eversept adding to their position in Avantor. A significant chunk of change, roughly $27.72 million, based on the quarterly averages. They held 3,176,644 shares by quarter’s end, worth $36.40 million. The paper gains, factoring in both the buy and the stock’s slow bleed, came to $24.87 million. Numbers. They can tell a story, if you know how to read the shadows.
What It Means, If Anything
Eversept’s stake in Avantor now sits at 1.83% of their U.S. equity holdings. Not a top five position. More like a side bet. A long shot. Their real money’s tied up in Vera Therapeutics, GSK, Ultragenyx, ABVX, and NTRA. Biotech, healthcare. The usual suspects. They’re playing the ecosystem, not a single card.
As of Friday, Avantor was trading at $7.80. A price that felt less like a valuation and more like a slow descent. Down 50% in a year. The S&P 500, meanwhile, was having a party. The contrast was… noticeable. Like a chipped glass at a champagne tasting.
The Details, Because Details Matter
| Metric | Value |
|---|---|
| Price (as of Friday) | $7.80 |
| Market capitalization | $5.3 billion |
| Revenue (TTM) | $6.55 billion |
| Net income (TTM) | ($530.20 million) |
Avantor deals in lab supplies, chemicals, and all the paraphernalia of science. They cater to biopharma, healthcare, education – anyone who needs beakers and test tubes. A solid business, in theory. But theory doesn’t pay the bills when the numbers turn sour.
The Gamble, And The Long Shot
Avantor’s revenue dipped 3% to $6.55 billion last year. The CEO, Emmanuel Ligner, is talking about a “Revival program.” A polite way of saying they’re trying to patch a leak with duct tape. They posted a net loss of $530.2 million, a stark contrast to the $711.5 million profit they enjoyed the year before. The numbers whispered a story of trouble.
Eversept’s bet isn’t about a quick turnaround. It’s about the potential. If Ligner’s “Revival” program actually takes hold, if they can stabilize growth and restore margins, then today’s depressed valuation might look different a few years down the line. That’s what Eversept is wagering. A long shot, maybe. But in this game, you play the odds, and hope the house doesn’t always win.
Read More
- Spotting the Loops in Autonomous Systems
- Seeing Through the Lies: A New Approach to Detecting Image Forgeries
- The Best Directors of 2025
- Staying Ahead of the Fakes: A New Approach to Detecting AI-Generated Images
- Gold Rate Forecast
- 20 Best TV Shows Featuring All-White Casts You Should See
- The Glitch in the Machine: Spotting AI-Generated Images Beyond the Obvious
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Umamusume: Gold Ship build guide
- Palantir and Tesla: A Tale of Two Stocks
2026-03-16 20:54